Parkinson's Disease clinical trials at UCSF
27 in progress, 13 open to eligible people
AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
open to eligible people ages 45-75
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
San Francisco, California and other locations
Exercise for Cognitive Excellence in Parkinson's Disease
open to eligible people ages 40-80
This study will evaluate the safety and feasibility of a home-based, virtually-supervised, combined high intensity endurance and resistance training program in people with Parkinson's disease. It will also evaluate the effects of exercise on…
San Francisco, California
Ketamine for Veterans With Parkinson's Disease
open to eligible people ages 40-80
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a …
San Francisco, California
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
open to eligible people ages 40 years and up
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor…
San Francisco, California and other locations
Psilocybin Therapy for Depression in Parkinson's Disease
open to eligible people ages 40-80
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
San Francisco, California
Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
open to eligible people ages 30 years and up
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD.…
San Francisco, California and other locations
PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
open to eligible people ages 18-80
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of…
San Francisco, California and other locations
Parkinson Disease of Exercise
open to eligible people ages 40-80
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with…
San Francisco, California and other locations
Understanding Motivation in Parkinson's Patients Through Neurophysiology
open to eligible people ages 18 years and up
The study aims to better understand motivation and value-based decision-making in Parkinson's patients through neurophysiology using Medtronic's Percept DBS device. By combining behavioral tasks with neural recordings, the study seeks to uncover how …
San Francisco, California
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
open to all eligible people
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
San Francisco, California and other locations
Parkinson Progression Marker Initiative Online (PPMI Online)
open to eligible people ages 18 years and up
Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive…
San Francisco, California
Parkinson's Foundation PD GENEration Genetic Registry
open to eligible people ages 18 years and up
Development of a central repository for PD-related genomic data for future research.
San Francisco, California and other locations
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
open to eligible people ages 30 years and up
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease…
San Francisco, California and other locations
Microbiota Intervention to Change the Response of Parkinson's Disease
Sorry, currently not accepting new patients, but might later
The clinical phenotype of Parkinson's disease (PD) is quite variable, as is the response to and side effects from medications. While many patients respond to carbidopa/levodopa early on, motor fluctuations and dyskinesias can become a problem as the …
San Francisco, California
Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Sorry, in progress, not accepting new patients
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD …
San Francisco, California and other locations
Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Sorry, in progress, not accepting new patients
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are…
San Francisco, California and other locations
Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Sorry, in progress, not accepting new patients
In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study. The main objective of…
San Francisco, California and other locations
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
Sorry, in progress, not accepting new patients
The purpose of the study is to demonstrate the safety and effectiveness of adaptive DBS (aDBS) for Parkinson's disease.
San Francisco, California and other locations
Adaptive Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease
Sorry, not yet accepting patients
The goal of this clinical trial is to learn if adaptive deep brain stimulation (DBS) can decrease or prevent freezing of gait in participants with Parkinson's disease.
San Francisco, California
Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease
Sorry, in progress, not accepting new patients
This is a single-center phase I clinical study aiming to improve gait functions in patients with Parkinson's disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device…
San Francisco, California
Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients
Sorry, in progress, not accepting new patients
This study will investigate cortical stimulation to treat mood and behavioral symptoms in Parkinson's disease patients.
San Francisco, California
ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
Sorry, in progress, not accepting new patients
This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion …
San Francisco, California and other locations
GDNF Gene Therapy for Parkinson's Disease
Sorry, in progress, not accepting new patients
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
San Francisco, California and other locations
ANPD001 in Parkinson Disease
Sorry, accepting new patients by invitation only
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells…
San Francisco, California and other locations
Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy
Sorry, in progress, not accepting new patients
This is an exploratory pilot study to identify neural correlates of specific motor signs in Parkinson's disease (PD) and dystonia, using a novel totally implanted neural interface that senses brain activity as well as delivering therapeutic…
San Francisco, California
Parkinson's And Zoledronic Acid
Sorry, in progress, not accepting new patients
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 …
San Francisco, California and other locations
Automated Imaging Differentiation of Parkinsonism
Sorry, in progress, not accepting new patients
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical…
San Francisco, California and other locations
Our lead scientists for Parkinson's Disease research studies include Nalin Gupta Doris D Wang, MD, PhD Joshua Woolley Caroline Tanner, MD, PhD Jill Ostrem, MD Nijee Luthra Marta San Luciano Palenzuela, MD Ellen R Bradley, MD Philip Starr Simon J Little, MBBS, PhD Vinil Shah.
Last updated: